X

Trial Profile

A Phase 3 Randomized Controlled Study of Renal Autologous Cell Therapy (REACT) in Subjects With Type 2 Diabetes and Chronic Kidney Disease (REGEN-006)

Status: Recruiting

Phase of Trial: Phase III

Latest Information Update: 18 Jun 2024

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Rilparencel (Primary)
Indications Renal failure
Focus Registrational; Therapeutic Use
Acronyms proact 1; REACT; REGEN-006
Sponsors ProKidney

Most Recent Events

17 Jun 2024 According to Prokidney media release, company announced the closing of $140 Million public offering of class A ordinary shares and concurrent registered direct offering to develop rilparencel for patients with advanced chronic kidney disease
17 Jun 2024 Last checked against ClinicalTrials.gov: US National Institutes of Health record.
10 Jun 2024 Planned number of patients changed from 600 to 685.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com